A Phase 2 Study of Enzastaurin in Participants With Follicular Lymphoma
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Enzastaurin (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 26 Dec 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 07 Oct 2014 Planned End Date changed from 1 Dec 2016 to 1 Mar 2015 according to ClinicalTrials.gov record.
- 30 Mar 2010 Planned end date changed from May 2009 to Dec 2016 as reported by ClinicalTrials.gov.